Physicians' Academy for Cardiovascular Education
The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.
This study validated six risk scores for ischemic stroke in patients with AF across the spectrum of kidney function. The Modified CHADS2 score showed most consistent predictive performance in all kidney function categories.
The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.
Experts in dialogue Two lipid experts discuss what the possible barriers are for implementing guidelines and not reaching goals with regard to LDL-c and how to overcome these barriers.
This subanalysis of the POPular Genetics trial showed that non-carriers of CYP2C19*2 or *3 LoF alleles treated with clopidogrel after primary PCI had less bleeding and similar thrombotic risk compared to patients on ticagrelor or prasugrel.
Danny Claassens presents the results of a prespecified subanalysis of the POPular Genetics trial, which focused on trombotic and bleeding outcomes in CYP2C19 genotype subgroups treated with clopidogrel or standard ticagrelor/prasugrel after PCI.
Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.
Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.
The PCSK9 inhibitor alirocumab has been approved by the US Food and Drug Administration (FDA) as an adjunct to other LDL-c lowering therapies for the treatment of adult patients with homozygous familial hypercholesterolemia.
Elevated non-HDL-c during adolescence, young- and mid-adulthood was associated with the presence of CAC in mid-adulthood. Adolescent non-HDL-c levels showed the strongest association with CAC in mid-adulthood.
Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.
Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.
